Monday, May 15, 2017 |
7:30 AM | Breakfast |
8:30 AM | Welcome and Introductions Linda L. Kusner, PhD, George Washington University Susan Klinger, Myasthenia Gravis Foundation of America and Nancy Law, Myasthenia Gravis Foundation of America Representative, The New York Academy of Sciences Alison Carley, PhD, The New York Academy of Sciences |
Session 1: Neuromuscular Junction (NMJ) Structure and FunctionSession Chair: Clarke R. Slater, PhD, Newcastle University, United Kingdom |
8:55 AM | Functional Organization of the Neuromuscular Junction: Introduction Clarke R. Slater, PhD, Newcastle University, United Kingdom |
9:05 AM | Presynaptic Plasticity in Myasthenia Gravis Mark M. Rich, MD, PhD, Wright State University |
9:25 AM | More Than a Pretzel: Spatial Distribution of the Neuromuscular Junction Components Tomasz J. Prószynski, PhD, Nencki Institute of Experimental Biology, Poland |
9:45 AM | Molecular Mechanisms of the Formation of Neuromuscular Junction Markus A. Ruegg, PhD, University of Basel, Switzerland |
10:05 AM | Is Age-Related Neuromuscular Junction Fragmentation a Sign of Altered Neuromuscular Junction Function? Clarke R. Slater, PhD, Newcastle University, United Kingdom |
10:25 AM | Networking Coffee Break |
Session 2: Congenital Myasthenic SyndromesSession Chair: Andrew G. Engel, MD, Mayo Clinic |
10:55 AM | Presynaptic Congenital Myasthenic Syndromes Caused by Mutations in SNAP25B and MUNC13-1 Andrew G. Engel, MD, Mayo Clinic |
11:15 AM | The Pathophysiological Mechanisms of CMS with Acetylcholinesterase Deficiency Claire Legay, PhD, Université Paris Descartes, France |
11:35 AM | Congenital Myasthenic Syndromes with Predominant Limb Girdle Weakness Hanns Lochmuller, MD, FAAN, Newcastle University, United Kingdom |
11:55 AM | Myasthenic Syndromes Due to Defects in COL13A1 and the N-Linked Glycosylation Pathway David Beeson, PhD, University of Oxford, United Kingdom |
12:15 PM | Therapeutic Strategies for Congenital Myasthenic Syndromes Jacqueline Palace, MD, John Radcliffe Hospital |
12:35 PM | Networking Lunch (Concurrent): Early Career Investigator and Underrepresented Minority Mentoring Lunch |
Session 3: Thymus in Myasthenia GravisSession Chair: Rozen le Panse, PhD, INSERM, France |
2:25 PM | Thymus Involvement in Myasthenia Gravis Rozen le Panse, PhD, INSERM, France |
2:35 PM | MGTX Histopathology Findings Alex Marx, MD, University of Heidelberg, Germany |
2:55 PM | Toll-like Receptors 7 and 9 in Myasthenia Gravis Thymus Paola Calvacante, PhD, Foundation Neurological Institute "Carlo Besta" |
3:15 PM | Networking Coffee Break |
Session 4: Serological Phenotypes and Unique Treatment ResponsesSession Chair: Angela Vincent, MSc, University of Oxford, United Kingdom |
3:45 PM | Overview of Serological Classification of Myasthenia Gravis Angela Vincent, MSc, University of Oxford, United Kingdom |
4:05 PM | Cortactin Antibodies in Myasthenia Gravis Isabel Illa, MD, PhD, Universitat Autonoma de Barcelona, Spain |
4:25 PM | MuSK Myasthenia Gravis Amelia Evoli, MD, Catholic Univeristy, Roma, Italy |
4:45 PM | A Unique Sub-Phenotype of Myasthenia Gravis Jeannine M. Heckmann, MB ChB, PhD, University of Cape Town, South Africa |
5:05 PM | Autoantibodies to Agrin in Myasthenia Gravis Arthur Melms, MD, Universitätsklinikum Erlangen, Germany |
5:25 PM | Day 1 Closing Remarks |
6:00 PM | Day 1 Poster Session and Networking Reception (Marriott Downtown) |
8:30 PM | Day 1 Adjourns |
|
Tuesday, May 16, 2017 |
7:15 AM | Sponsored Breakfast Session This breakfast and discussion is generously supported and presented by Alexion Panel Discussion: Characterizing Unmet Needs of Patients with Myasthenia Gravis Moderator: Karen Gondek Panelists: James F Howard, Jr, MD, University of North Carolina at Chapel Hill School of Medicine Richard J. Nowak, MD, MS, Yale University School of Medicine Gil Wolfe, MD, FAAN, University at Buffalo Jacobs School of Medicine and Biomedical Sciences Additional panelists to be announced |
Session 5: Mechanisms of Autoimmunity (basic, including diseases other than Myasthenia Gravis)Session Chair: Sonia Berrih-Aknin, DSc, INSERM, France |
8:30 AM | Introduction to Autoimmunity Sonia Berrih-Aknin, DSc, INSERM, France |
8:40 AM | Keynote Address: T cell Function in Autoimmunity Vijay Kuchroo, DVM, PhD, Harvard Institutes of Medicine |
9:10 AM | Regulatory B cells in Health and Disease Claudia Mauri, PhD, University College London, United Kingdom |
9:30 AM | Estrogen-Mediated Downregulation of AIRE Influences the Gender-Bias in Autoimmune Diseases Nadine Dragin, PhD, Institute of Myology, France |
9:50 AM | Expanding Field of IgG4 Autoimmune Diseases Maartje Huijbers, PhD, Leiden University Medical Center, Netherlands |
10:10 AM | Networking Coffee Break |
Session 6: Mechanisms of Myasthenia Gravis Autoimmunity — UpdatesSession Chair: Kevin C. O'Connor, PhD, Yale School of Medicine |
10:40 AM | Introduction to Myasthenia Gravis Autoimmunity Kevin C. O'Connor, PhD, Yale School of Medicine |
10:50 AM | Mechanisms of B Cell and T Cell Immunopathology in Myasthenia Gravis Kevin O'Connor, PhD, Yale School of Medicine |
11:10 AM | Immune Checkpoint Markers in Myasthenia Gravis Patients John S. Yi, PhD, Duke University Medical Center |
11:30 PM | Cytokine Production in Myasthenia Gravis Patients Vuslat Yilmaz, PhD, Istanbul University, Turkey |
11:50 AM | Circulating MicroRNAs in Myasthenia Gravis Anna Rostedt Punga, MD, PhD, Uppsala University, Sweden |
12:10 PM | Networking Lunch |
Session 7: Day 2 Hot Topic Short Talks (Selected from Submitted Abstracts)Session Chair: To Be Announced |
1:55 PM | Speaker to Be Announced |
2:05 PM | Speaker to Be Announced |
2:15 PM | Speaker to Be Announced |
2:25 PM | Speaker to Be Announced |
Session 8: Clinical Trials UpdateSession Chair: Henry Kaminski, MD, George Washington University |
2:35 PM | Clinical Trials for Myasthenia Gravis Henry Kaminski, MD, George Washington University |
2:45 PM | Eculizumab Results in Improvement in Activities of Daily Living and Muscle Strength in Refractory Generalized Myasthenia Gravis Patients Compared with Placebo James F. Howard, Jr., MD, University of North Carolina at Chapel Hill |
3:05 PM | MGTX Primary and Secondary Outcomes Gil I. Wolfe, MD, University of Buffalo |
3:25 PM | A Phase 1b Clinical Trial of CV-MG01, Acetylcholine Receptor Mimetic Peptides Rudy Mercelis, MD, PhD, Antwerp University Hospital, Belgium |
3:45 PM | Networking Coffee Break |
Session 9: Upcoming, Ongoing or Future Trials in Myasthenia GravisSession Chair: Jeffrey Guptill, MD, Duke University |
4:15 PM | Overview Introduction Jeffrey Guptill, MD, Duke University Medical Center |
4:25 PM | B Cell Targeted Treatment in Myasthenia Gravis (BeatMG): A Phase 2 Trial of Rituximab in Myasthenia Gravis Richard J. Nowak, MD, MS, Yale University School of Medicine |
4:45 PM | AChR-Specific Immunosuppressive Therapy of Myasthenia Gravis Jon Martin Lindstrom, PhD, University of Pennsylvania |
5:05 PM | Difficulty with Clinical Trials — What We Have Learned So Far? Michael Benatar, MD, PhD, University of Miami |
5:25 PM | Myasthenia Gravis Foundation of America Philanthropist of the Year Award Presentation: Honoring Mona Roth Nancy Law, Myasthenia Gravis Foundation of America, and Robert Ruff, MD, PhD, Case Western Reserve University School of Medicine |
5:40 PM | Day 2 Networking Reception |
7:00 PM | Day 2 Adjourns |
|
Wednesday, May 17, 2017 |
7:30 AM | Breakfast |
Session 10: Acetylcholine Receptor Animal ModelsSession Chair: Linda L. Kusner, PhD, George Washington University |
8:30 AM | Acetylcholine Receptor Animal Models and Complement Linda L. Kusner, PhD, George Washington University |
8:50 AM | Pathogenic Mechanisms and Treatment Strategies for AChR-MG in Preclinical Models Pilar Martinez-Martinez, PhD, Maastricht University, Netherlands |
9:10 AM | Toll-like Receptor (TLR) Agonists to Induce Experimental Autoimmune Myasthenia Gravis (EAMG) Rozen le Panse, PhD, INSERM, France |
9:30 AM | Electrophysiology of Myasthenia Gravis Animal Models Jaap J. Plomp, PhD, Leiden University Medical Center, Netherlands |
9:50 AM | Networking Coffee Break |
Session 11: Other Animal Models in Myasthenia GravisSession Chair: William Donald Phillips, PhD, University of Sydney, Australia |
10:20 AM | Does Anti-MuSK Cause Myasthenia Simply by Inhibiting Agrin/MuSK Signaling? William Donald Phillips, PhD, University of Sydney, Australia |
10:40 AM | Anti-MuSK IgG4 in the Passive Transfer Model Jan Verschuuren, MD, PhD, Leiden University Medical Center, Netherlands |
11:00 AM | Experimental Studies on Seronegative Myasthenia Angela Vincent, MSc, University of Oxford, United Kingdom |
11:20 AM | Using the Mouse Passive Transfer Model of Lambert–Eaton Myasthenic Syndrome (LEMS) to Explore Disease Pathology and Test New Therapeutic Leads Stephen D. Meriney, PhD, University of Pittsburgh |
11:40 AM | Lrp4 and Agrin Antibodies in Myasthenia Gravis Lin Mei, PhD, Augusta University |
12:00 PM | Remembering Claudio Mazia, MD, University of Buenos Aires, Argentina |
12:10 PM | Networking Luncheon |
Session 12: Day 3 Hot Topic Short Talks (Selected from Submitted Abstracts)Session Chair: To Be Announced |
1:25 PM | Speaker to Be Announced |
1:35 PM | Speaker to Be Announced |
1:45 PM | Speaker to Be Announced |
1:55 PM | Speaker to Be Announced |
2:05 PM | Speaker to Be Announced |
2:15 PM | Networking Coffee Break |
Session 13: Treatment Guidelines from Around the WorldSession Chair: Donald B. Sanders, MD, Duke University Medical Center |
2:45 PM | International Consensus Guidance Statements for Myasthenia Gravis Treatment Donald B. Sanders, MD, Duke University Medical Center |
3:15 PM | Treatment Guidelines for Myasthenia Gravis in Japan Hiroyuki Murai, MD, International University of Health and Welfare, Japan |
3:35 PM | The Myasthenia Gravis Guidelines of the Association of British Neurologists Jon D. Sussman, PhD, FRCP, Greater Manchester Neuroscience Centre, United Kingdom |
3:55 PM | Unique Treatment Challenges in South America Valeria L. Salutto, MD, Alfredo Lanari Institute of Medical Investigations, University of Buenos Aires, Argentina |
4:15 PM | Panel Discussion: Comparing and Contrasting Treatment Strategies around the World Moderator: Henry Kaminski, MD, George Washington University Panelists: Hiroyuki Murai, MD, International University of Health and Welfare, Japan Valeria L. Salutto, MD, Alfredo Lanari Institute of Medical Investigations, University of Buenos Aires, Argentina Donald B. Sanders, MD, Duke University Medical Center Jon Sussman, PhD, FRCP, Greater Manchester Neuroscience Centre, United Kingdom Gil I. Wolfe, MD, University of Buffalo |
4:45 PM | Closing Remarks |
4:50 PM | Meeting Concludes |